Genetic deletion of caspase-2 accelerates MMTV/c-neu-driven mammary carcinogenesis in mice

Cell Death and Differentiation

Volumn 20, Issue 9, 2013, Pages 1174-1182

  Parsons, M J ^a,b,c   McCormick, L ^a   Janke, L ^a   Howard, A ^a   Bouchier Hayes, L ^b,c   Green, D R ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b CENTER FOR CELL AND GENE THERAPY   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

apoptosis; caspase; oncogene

Indexed keywords

BIOLOGICAL MARKER; CASPASE 2; FLUOROURACIL; NOCODAZOLE; PROTEIN MDM2; PROTEIN P21; PROTEIN P53; SPARFOSIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CARCINOGENESIS; BREAST CARCINOMA; CANCER MORPHOLOGY; CELL DIVISION; CELL PROLIFERATION; CELL SIZE; CELL STRUCTURE; CONTROLLED STUDY; EMBRYO; FEMALE; FIBROBLAST; GENE DELETION; GENETIC MARKER; GENOMIC INSTABILITY; LD 50; MITOSIS; MITOSIS INDEX; MOUSE; MOUSE MAMMARY TUMOR ONCOVIRUS; MULTINUCLEAR CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REGULATORY MECHANISM;

ANIMALIA; MAMMALIA; MOUSE MAMMARY TUMOR VIRUS; MUS;

ANIMALS; CARCINOGENESIS; CASPASE 2; CELL CYCLE; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; DEATH DOMAIN RECEPTOR SIGNALING ADAPTOR PROTEINS; FEMALE; MAMMARY NEOPLASMS, ANIMAL; MAMMARY TUMOR VIRUS, MOUSE; MICE; MICE, KNOCKOUT; PROTO-ONCOGENE PROTEINS C-MDM2; RHO GTP-BINDING PROTEINS; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 84882289067     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2013.38     Document Type: Article

References (37)

1. Bouchier-Hayes L, Green DR. Caspase-2: the orphan caspase. Cell Death Differ 2012; 19: 51-57.
2. Ho LH, Taylor R, Dorstyn L, Cakouros D, Bouillet P, Kumar S. A tumor suppressor function for caspase-2. Proc Natl Acad Sci USA 2009; 106: 5336-5341.
3. Tu S, McStay GP, Boucher LM, Mak T, Beere HM, Green DR. In situ trapping of activated initiator caspases reveals a role for caspase-2 in heat shock-induced apoptosis. Nat Cell Biol 2006; 8: 72-77.
4. Ho LH, Read SH, Dorstyn L, Lambrusco L, Kumar S. Caspase-2 is required for cell death induced by cytoskeletal disruption. Oncogene 2008; 27: 3393-3404.
5. Troy CM, Rabacchi SA, Friedman WJ, Frappier TF, Brown K, Shelanski ML. Caspase-2 mediates neuronal cell death induced by beta-amyloid. J Neurosci 2000; 20: 1386-1392.
6. Stefanis L, Troy CM, Qi H, Shelanski ML, Greene LA. Caspase-2 (Nedd-2) processing and death of trophic factor-deprived PC12 cells and sympathetic neurons occur independently of caspase-3 (CPP32)-like activity. J Neurosci 1998; 18: 9204-9215.
7. Sidi S, Sanda T, Kennedy RD, Hagen AT, Jette CA, Hoffmans R et al. Chk1 suppresses a caspase-2 apoptotic response to DNA damage that bypasses p53, Bcl-2, and caspase-3. Cell 2008; 133: 864-877.
8. Nutt LK, Buchakjian MR, Gan E, Darbandi R, Yoon SY, Wu JQ et al. Metabolic control of oocyte apoptosis mediated by 14-3-3zeta-regulated dephosphorylation of caspase-2. Dev Cell 2009; 16: 856-866.
9. Dorstyn L, Puccini J, Wilson CH, Shalini S, Nicola M, Moore S et al. Caspase-2 deficiency promotes aberrant DNA-damage response and genetic instability. Cell Death Differ 2012; 19: 1288-1298.
10. Andersen JL, Johnson CE, Freel CD, Parrish AB, Day JL, Buchakjian MR et al. Restraint of apoptosis during mitosis through interdomain phosphorylation of caspase-2. EMBO J 2009; 28: 3216-3227.
11. Holleman A, den Boer ML, Kazemier KM, Beverloo HB, von Bergh AR, Janka-Schaub GE et al. Decreased PARP and procaspase-2 protein levels are associated with cellular drug resistance in childhood acute lymphoblastic leukemia. Blood 2005; 106: 1817-1823.
12. Estrov Z, Thall PF, Talpaz M, Estey EH, Kantarjian HM, Andreeff M et al. Caspase 2 and caspase 3 protein levels as predictors of survival in acute myelogenous leukemia. Blood 1998; 92: 3090-3097.
13. Faderl S, Estrov Z. Detection of residual disease in childhood acute lymphoblastic leukemia. N Engl J Med 1999; 340: 152-153; author reply 153-154.
14. Faderl S, Estrov Z. The clinical significance of caspase regulation in acute leukemia. Leuk Lymphoma 2001; 40: 471-481.
15. Muller WJ, Sinn E, Pattengale PK, Wallace R, Leder P. Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 1988; 54: 105-115.
16. Anisimov VN, Popovich IG, Alimova IN, Zabezhinski MA, Semenchenko AV, Yashin AI. Number of pregnancies and ovariectomy modify mammary carcinoma development in transgenic HER-2/neu female mice. Cancer Lett 2003; 193: 49-55.
17. Herschkowitz JI, Simin K, Weigman VJ, Mikaelian I, Usary J, Hu Z et al. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol 2007; 8: R76.
18. Livingstone LR, White A, Sprouse J, Livanos E, Jacks T, Tlsty TD. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 1992; 70: 923-935.
19. Yin Y, Tainsky MA, Bischoff FZ, Strong LC, Wahl GM. Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell 1992; 70: 937-948.
20. Smith KA, Chernova OB, Groves RP, Stark MB, Martinez JL, Davidson JN et al. Multiple mechanisms of N-phosphonacetyl-L-aspartate resistance in human cell lines: carbamyl-P synthetase/aspartate transcarbamylase/dihydro-orotase gene amplification is frequent only when chromosome 2 is rearranged. Proc Natl Acad Sci USA 1997; 94: 1816-1821.
21. Wahl GM, Padgett RA, Stark GR. Gene amplification causes overproduction of the first three enzymes of UMP synthesis in N-(phosphonacetyl)-L-aspartate- resistant hamster cells. J Biol Chem 1979; 254: 8679-8689.
22. Manzl C, Peintner L, Krumschnabel G, Bock F, Labi V, Drach M et al. PIDDosomeindependent tumor suppression by Caspase-2. Cell Death Differ 2012; 19: 1722-1732.
23. Rowse GJ, Ritland SR, Gendler SJ. Genetic modulation of neu proto-oncogene-induced mammary tumorigenesis. Cancer Res 1998; 58: 2675-2679.
24. Taneja P, Frazier DP, Kendig RD, Maglic D, Sugiyama T, Kai F et al. MMTV mouse models and the diagnostic values of MMTV-like sequences in human breast cancer. Expert Rev Mol Diagn 2009; 9: 423-440.
25. Maroulakou IG, Oemler W, Naber SP, Tsichlis PN. Akt1 ablation inhibits, whereas Akt2 ablation accelerates, the development of mammary adenocarcinomas in mouse mammary tumor virus (MMTV)-ErbB2/neu and MMTV-polyoma middle T transgenic mice. Cancer Res 2007; 67: 167-177.
26. Strange R, Li F, Saurer S, Burkhardt A, Friis RR. Apoptotic cell death and tissue remodelling during mouse mammary gland involution. Development 1992; 115: 49-58.
27. Gisselsson D, Jin Y, Lindgren D, Persson J, Gisselsson L, Hanks S et al. Generation of trisomies in cancer cells by multipolar mitosis and incomplete cytokinesis. Proc Natl Acad Sci USA 2010; 107: 20489-20493.
28. Linke SP, Clarkin KC, Di Leonardo A, Tsou A, Wahl GM. A reversible, p53-dependent G0/G1 cell cycle arrest induced by ribonucleotide depletion in the absence of detectable DNA damage. Genes Dev 1996; 10: 934-947.
29. Oliver TG, Meylan E, Chang GP, Xue W, Burke JR, Humpton TJ et al. Caspase-2-mediated cleavage of Mdm2 creates a p53-induced positive feedback loop. Mol Cell 2011; 43: 57-71.
30. Hu W, Feng Z, Teresky AK, Levine AJ. p53 regulates maternal reproduction through LIF. Nature 2007; 450: 721-724.
31. Yoo NJ, Lee JW, Kim YJ, Soung YH, Kim SY, Nam SW et al. Loss of caspase-2,-6 and-7 expression in gastric cancers. Acta Pathol Microbiol Scand 2004; 112: 330-335.
32. Heikaus S, Pejin I, Gabbert HE, Ramp U, Mahotka C. PIDDosome expression and the role of caspase-2 activation for chemotherapy-induced apoptosis in RCCs. Cell Oncol 2010; 32: 29-42.
33. Jones TD, Eble JN, Wang M, MacLennan GT, Delahunt B, Brunelli M et al. Molecular genetic evidence for the independent origin of multifocal papillary tumors in patients with papillary renal cell carcinomas. Clin Cancer Res 2005; 11: 7226-7233.
34. Kan Z, Jaiswal BS, Stinson J, Janakiraman V, Bhatt D, Stern HM et al. Diverse somatic mutation patterns and pathway alterations in human cancers. Nature 2010; 466: 869-873.
35. Weber M, Hellmann I, Stadler MB, Ramos L, Paabo S, Rebhan M et al. Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome. Nat Genet 2007; 39: 457-466.
36. Christensen BC, Marsit CJ, Houseman EA, Godleski JJ, Longacker JL, Zheng S et al. Differentiation of lung adenocarcinoma, pleural mesothelioma, and nonmalignant pulmonary tissues using DNA methylation profiles. Cancer Res 2009; 69: 6315-6321.
37. Bergeron L, Perez GI, Macdonald G, Shi L, Sun Y, Jurisicova A et al. Defects in regulation of apoptosis in caspase-2-deficient mice. Genes Dev 1998; 12: 1304-1314.